Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $1.1 million.

  • Syndax Pharmaceuticals' Change in Accured Expenses fell 9476.16% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 8767.6%. This contributed to the annual value of $19.1 million for FY2024, which is 2873.48% up from last year.
  • Syndax Pharmaceuticals' Change in Accured Expenses amounted to $1.1 million in Q3 2025, which was down 9476.16% from $17.9 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Accured Expenses peaked at $21.0 million during Q3 2024, and registered a low of -$9.2 million during Q1 2023.
  • For the 5-year period, Syndax Pharmaceuticals' Change in Accured Expenses averaged around $3.3 million, with its median value being $1.1 million (2025).
  • Within the past 5 years, the most significant YoY rise in Syndax Pharmaceuticals' Change in Accured Expenses was 930487.8% (2022), while the steepest drop was 89381.44% (2022).
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $638000.0 in 2021, then skyrocketed by 1618.81% to $11.0 million in 2022, then crashed by 31.58% to $7.5 million in 2023, then surged by 55.34% to $11.7 million in 2024, then plummeted by 90.54% to $1.1 million in 2025.
  • Its Change in Accured Expenses stands at $1.1 million for Q3 2025, versus $17.9 million for Q2 2025 and -$2.5 million for Q1 2025.